A human breast cancer cell line, MCF-7, transiently transfected with a chimeric estrogen receptor (Gal4-HEG0) and a luciferase reporter plasmid (17m5-G-Luc), was used to investigate the estrogenic activity of benzo [a]
tion, and progression, and is abundantly distributed in the environment. Bioactivation of B[a]P by cytochrome P450 enzymes has been shown to be necessary in order for it to acquire its mutagenic and carcinogenic properties (ATSDR, 1990; Bauer et al., 1995; Kim et al., 1998) .
The common phenolic metabolites of B[a]P include the 3-OH, 7-OH, and 9-OH species, which result from hydroxylase activity shown to be mediated through the CYP1A, 2C, and 3A families (Gautier et al., 1996; Monteith et al., 1987; Shou et al., 1994) . Further metabolism to the (-)-B[a]P-7R-trans-7,8-dihydrodiol (7, and the B[a]P-trans-9,10-dihydrodiol (9,10-OH) occurs in the presence of microsomal epoxide hydrolase, which may lead to the formation of the ultimate carcinogen (Ϯ)B[a]P-r7,t-8-dihydrodiol-t-9,10-epoxide (BPDE) (Kim et al., 1998; Slaga et al., 1979) .
The steric resemblance of the PAHs including B[a]P to steroid molecules led to the postulation, as far back as the 1950s, that they would have the ability to act on the same site as steroid hormones (Yang et al., 1961) . PAHs have been evaluated for hormonelike activity in both in vivo and in vitro assays (Clemons et al., 1998; Morreal et al., 1982 Morreal et al., , 1979 Tran et al., 1996) , and demonstrated both estrogenic and antiestrogenic activities. These demonstrated activities might be the consequence of the promiscuous binding capacity of the estrogen receptor, due to the structure of its binding cavity (Brzozowski et al., 1997) .
Gene transactivation assays have been proposed as part of a tiered testing strategy by the Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) for the identification of potential endocrine-active chemicals. These in vitro systems are proposed for use in screening for chemicals and mixtures that interact with the estrogen/androgen hormone receptor systems. Some investigators have raised the issue that compounds that require metabolic activation, or that act through non-receptor-mediated pathways, could potentially be missed in such a system if the target cells lacked the necessary cellular machinery (Gierthy et al., 1996; Loukovaara et al., 1995; Mousavi and Adlercreutz, 1992) .
Therefore, as part of a larger study investigating the feasi-bility of incorporating exogenous metabolic capacity into such assays, we investigated the metabolic competence of a model ER-␣ transactivation system utilizing B[a]P as one of our test compounds. This assay utilizes the MCF-7 human breast cancer cell line transiently transfected with a chimeric ER-␣ expression plasmid and a responsive luciferase reporter. The utility of this system for the analysis of ER-mediated endocrine activity has previously been demonstrated (Zacharewski et al., 1994) , with B[a]P having recently been shown to exhibit significant activity in this assay system (Clemons et al., 1998) . B[a]P is known to bind to the Ah receptor and induce the activity of cytochrome P450 metabolic enzymes (Harris et al., 1988; Kamps and Safe, 1987; Merchant et al., 1992) . These properties of B[a]P made it an ideal compound for evaluating the metabolic capabilities of the MCF-7 cell culture system and for exploring the potential interaction of cellular metabolism and ER-mediated events.
In this study, we characterized the metabolite profile of B[a]P in the MCF-7 cell culture system and found the cells to be competent to metabolize B[a]P to a series of mono-and diphenolic products, as has previously been shown in primary cultures of mammary epithelial cells (Bartley and Stampfer, 1985; Moore et al., 1986; Tischler et al., 1991) . Furthermore, we assessed the estrogenic activity of B[a]P and its metabolites in the ER-␣ reporter gene assay. The P450 inhibitor and Ah receptor antagonist ␣-NF (Bauer et al., 1995; Merchant et al., 1993; Nesnow et al., 1982; Rämet et al., 1995) was also used to further elucidate the relationship between metabolism and the estrogenic activity of B[a]P and its metabolites.
MATERIALS AND METHODS

Reagents. [7-
14 C]B[a]P (26.6 mCi/mmol) was purchased from Amersham Corp. (Arlington Heights, IL). The original toluene solvent was removed by evaporation under a stream of dry nitrogen and reconstituted in dimethylsulfoxide (DMSO). 17␤-estradiol (E2) was obtained from the Sigma Chemical Company (St. Louis, MO) and benzo [a] pyrene (B[a]P) from Chem Service (West Chester, PA). 3-OH, 9-OH, (ϩ-)-trans 7,8-OH, and trans 9,10-OH were purchased from the National Cancer Institute Carcinogen Repository (Kansas City, MO). ICI 182,780 was purchased from Tocris Cookson (Ballwin, MO). All reagents used in the treatment of transfected cultures were dissolved in DMSO in amber glass vials and operations were performed under subdued lighting. Phenol red-free Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and medium supplements were purchased from Life Technologies (Grand Island, NY). Dextran charcoal-stripped fetal bovine serum (FBS-DCC) was obtained from Hyclone (Logan, UT).
Cell culture. MCF-7 cells (obtained from Dr. L. Murphy, University of Manitoba, Winnipeg, Manitoba) were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 15 mM HEPES augmented with 50 g/ml gentamicin, penicillin/streptomycin (100 IU/ml/100 g/ml), and amphotericin B (2.5 g/ml). Cells were maintained at 3% CO 2 and 95% humidity.
Transfection. Cells were plated in triplicate in 96-well plates at a density of 6 -8 ϫ 10 3 cells/well in 5% FBS-DCC (Hyclone, Logan, UT). After attachment and growth for 6 h, the cells were transfected using Lipofectin™ (Life Technologies). To each well was added 50 ng of the ␤-galactosidase (␤-gal) expression vector pCH110 (Pharmacia, Piscataway, NJ), 150 ng of 17m5-G-Luc, the Gal4-regulated luciferase reporter vector, and 5 ng of Gal4-HEG0, an ER expression vector (both provided by P. Chambon, INSERM, France). The plasmids were transfected in serum-free, antibiotic-free DMEM supplemented with 2 mM L-glutamine. Cells were allowed to incubate overnight at 37°C in a humidified atmosphere of 3% CO 2 /air. Sixteen to eighteen hours following transfection, the plates were blotted dry on sterile paper towels; the cells were then treated in triplicate with E2, B[a]P and its metabolites, ␣-NF, or DMSO (Sigma) in 5% FBS-DCC. The ER agonist E2 was used over a range of concentrations from 10 -12 to 10 -8 M, with DMSO as solvent. The pure antiestrogen ICI 182,780 (Wakeling et al., 1991) was used in all assays in combination with E2 to verify that the reporter gene activity was strictly ER mediated. Following treatment, wells were washed with PBS, and 50 l lysis buffer (Promega, Madison, WI) was added to each well. Thawing the plates after freezing at -70°C facilitated cell lysis. Aliquots from each well were divided into two 96-well plates for luciferase and ␤-gal activity determination. The reference plasmid pCH110 was cotransfected as an internal control to correct for variations in transfection efficiency. The values presented are units of luciferase activity normalized to the ␤-gal activity from individual wells. Experiments were evaluated with fold induction being the endpoint of interest. Treatment regimens that resulted in a reduced ␤-gal activity relative to that of transfected cultures exposed to E2 under unaltered media conditions were considered cytotoxic and were not used for further analysis. Note that carrier solvent (DMSO) concentrations did not exceed 0.3% in these assays, nor was the osmolality or pH of the E2 or B[a]P dosing solutions changed by Ϯ 6 mOsMol or Յ 0.06 units, respectively, relative to vehicle-treated controls.
Luciferase activity assay. 10 l of lysate was combined with 100 l of luciferase assay reagent (Promega), and luminescence was determined immediately using a Packard Topcount NXT™ luminescence counter (Packard Instrument Company, Meriden, CT).
␤-galactosidase activity assay. The ␤-gal activity was measured using a chemiluminescent kit (Tropix Inc, Bedford, MA). ␤-gal activity was initiated with 70 l of galactosidase reaction buffer added to 10 l of the cell lysate, followed by a 30-min room temperature incubation. After the reaction was stopped by addition of 100 l of the Accelerator II stop buffer, the chemiluminescence was measured in the Packard Topcount NXT™ luminescence counter.
HPLC analysis of [ 14 C]B[a]P metabolites.
Following 24 h of exposure, 20% v/v acetonitrile was added to the treated cultures. The mixture was allowed to incubate for 5 min at room temperature and medium and lysate were aliquoted into 15-ml tubes. Cell debris was removed by centrifugation at 600 ϫ g for 5 min; the supernatant was used for metabolite analysis. Samples were thawed to room temperature and a portion of each was transferred to an autosampler vial for analysis. An aliquot (400 l) of each sample was injected using a Waters model 717 Plus autosampler (Waters Corporation, Milford, MA) into a reverse-phase high-pressure liquid chromatographic (HPLC) system. The pumping system was a Hitachi model L-6200A (Hitachi, Ltd., Tokyo, Japan). The separation of sample components was achieved using a 15 cm ϫ 4.6 mm i.d. analytical column packed with 5 m Zorbax SB-C8 (MAC-MOD Analytical, Inc., Chadds Ford, PA). The mobile phase system consisted of A: 1% acetic acid in water, and B: 1% acetic acid in acetonitrile. The mobile phase gradient program consisted of a 2-min isocratic initial hold at 60/40 A/B, then a 20-min linear gradient down to 10/90 A/B, with a hold at 10/90 A/B for 5 min. An ultraviolet (UV) detector (Kratos SpectroFlow 773, Applied Biosystems, Foster City, CA) set at 254 nm was used to monitor the effluent prior to collection of 15-s fractions using an Isco FOXY 200 fraction collector (Isco, Inc., Lincoln, NE). A 5-ml aliquot of liquid scintillant (Ultima Flo M, Packard, Meriden, CT) was added to each fraction. The fractions were counted for radioactivity using a Beckman LS 6000 IC liquid scintillation counter (Beckman Instruments, Inc., Fullerton, CA) in the 14 C mode. Radiochromatograms for each injection were reconstructed from the counted fractions. Metabolite assignments were determined by comparison to authentic standards purchased from the National Cancer Institute Carcinogen Repository (Kansas City, MO).
Data analysis. Data points are expressed as the mean Ϯ SD of triplicate measurements. The values presented are units of luciferase activity normalized to the ␤-gal activity from individual wells. Data were evaluated using the fold induction of the normalized luciferase activity in the B[a]P/E2-treated relative to the DMSO-treated cultures. Unless otherwise stated, experiments were performed at least three times. Data were analyzed for statistical differences between control and treated groups using two-tailed t-test and Dunnett's test relative to the control group for post-hoc comparisons.
RESULTS
B
[a]P in our model ER-␣ transactivation system elicited demonstrable estrogenlike activity relative to the natural ER agonist E2 (Fig. 1) . The EC50 for B[a]P was approximately 1 M, which was about four orders of magnitude greater than that for E2 (0.1 nM). Furthermore, B[a]P did not exhibit full agonist activity, defined as fold induction, relative to E2. The fact that B[a]P had previously been demonstrated to bind to the Ah receptor (Kamps and Safe, 1987) led to the initial investigation of the effect of a known Ah receptor antagonist and P450 inhibitor, ␣-NF (Merchant et al., 1993; Wilhelmsson et al., 1994) , on the B[a]P response. ␣-NF at a 2-M concentration ( Fig. 2A) significantly inhibited the response to 1-M B[a]P (p Ͻ 0.01). This concentration of ␣-NF produced a minimal induction of luciferase activity ( Fig. 2A) , and did not decrease the response to E2 (Fig. 2B) , indicating a specificity for the response produced by B[a]P. As shown in Figures 2A and B, ICI 182,780, a well-characterized ER antagonist (Wakeling et al., 1991) , was able to completely inhibit the response generated by both E2 and B[a]P.
A further investigation of the responses generated by E2 and B[a]P as shown (Fig. 2B) demonstrates that concentrations of both compounds that produced submaximal reporter activity (0.1 nM E2 and 1 M B[a]P), when added together, generated a response that was completely blocked by ICI 182,780, but not by ␣-NF. A metabolic profile of the MCF-7 cell assay system showed the production of a number of mono-and diphenolic B[a]P metabolites (Fig. 3A) . These include the 3-OH and 9-OH as well as the 7,8-OH and 9,10-OH species. In the presence of ␣-NF, shown in Figure 3B , the production of these metabolites was markedly inhibited. These data led to the analysis of various B[a]P metabolites (3-OH and 9-OH as well as the 7,8-OH and 9,10-OH) for potential induction of luciferase reporter activity.
Concurrently generated, representative dose-response curves for E2 and the 3-OH, 9-OH, and 9,10-OH metabolites of B[a]P are shown (Fig. 4) . Concentrations of the 3-OH and 9-OH were 
FIG. 1. Dose-response curves for the activation of ER-␣ transcription by E2 (asterisk) and B[a]P (diamond)
. MCF-7 cell cultures were transiently transfected as described under Materials and Methods and incubated with the concentrations shown for 24 h. Results are from a representative experiment and expressed as fold induction over the DMSO vehicle Ϯ SD with each point being the mean of triplicate measurements. Experiments were repeated at least eight times for both compounds. evaluated at Յ 5 M, and the 9,10-OH metabolite was evaluated at Յ 10 M. Concentrations above these levels induced cytotoxicity, as indicated by ␤-galactosidase activity measurements. By comparison, the 7,8-OH metabolite exhibited no significant induction of luciferase activity upon exposure to transfected MCF-7 cultures (data not shown). As shown, the 3-OH and 9-OH metabolites of B[a]P were comparable in the magnitude of their responses relative to E2, whereas the 9,10-OH metabolite produced minimal reporter activity even at the highest concentrations tested. The EC50 values for the 3-OH and 9-OH species were approximately 1.2 M and 0.7 M, respectively.
In order to ascertain whether these responses were ERmediated, experiments were performed in the presence of the ER antagonist ICI 182,780. The results reflected the complete inhibition of the induced reporter activity as shown (Fig. 5A) . Furthermore, the effect of ␣-NF on reporter activity was evaluated. As shown (Fig. 5B) , ␣-NF did not have any effect on the responses of the 3-OH. There was a tendency towards a decrease in the response produced by the 9-OH metabolite, which achieved statistical significance (p Ͻ 0.05) over the four experiments performed. The effect of ␣-NF on the 9,10-OH metabolite could not be determined due to the low level of response induced by the latter.
Not only did the 7,8-OH metabolite fail to produce significant reporter activity (data not shown), it also induced a doserelated cytotoxicity at concentrations Ն 100 nM (p Ͻ 0.01), as determined by ␤-galactosidase activity (Fig. 6) . Interestingly, ␣-NF appeared to have a cytoprotective effect on the MCF-7 cells in the assay system, as demonstrated by the ability of ␣-NF to consistently produce a recovery of the ␤-galactosidase activity in cultures treated with the 7,8-OH metabolite.
DISCUSSION
The ER previously has been shown to exhibit an ability to bind to an array of compounds with a degree of structural diversity (Kuiper et al., 1998) . The recently elucidated crystal structure of the ER-␣ ligand-binding domain complexed with E2 provided important clues to explain this observed promiscuity (Brzozowski et al., 1997) . The capability of the receptor to bind such diverse ligands can be attributed to the size and structure of its binding cavity. In fact, it was postulated many years ago that a molecular similarity existed between carcinogenic PAHs and estrogens (Yang et al., 1961) , leading to the investigation of the ER-binding properties of these compounds.
The hydroxylated PAHs 3,9-dihydroxy-benz[a]anthracene and 3,9-dihydroxy-7,12-dimethylbenz[a]anthracene were weakly estrogenic in rat bioassays in terms of both in vitro binding to   FIG. 4 . Dose-response curves for the activation of ER-␣ transcription by E2 (square), 3-OH (asterisk), 9-OH (diamond), and the 9,10-OH (triangle) metabolites of B[a]P. MCF-7 cell cultures were transiently transfected as described under Materials and Methods and incubated with the concentrations shown for 24 h. Results are from a representative experiment and are expressed as fold induction over the DMSO vehicle Ϯ SD with each point being the mean of triplicate measurements. Experiments were repeated at least three times for all compounds. the ER and increased uterine wet weight (Morreal et al., 1979) . The 1-OH, 2-OH, 5-OH, 6-OH, 11-OH, and 12-OH, but not the 4-OH metabolites of B[a]P, exhibited competition for binding to the ER in the cytosol of rat uterus (Ebright et al., 1986) . Previous studies have also shown that B[a]P may have a weak mitogenic activity in primary and tumor-derived human mammary epithelial cell cultures (Katdare et al., 1998; Tannheimer et al., 1997 Tannheimer et al., , 1998 . Recent studies utilizing a chimeric ER-␣ receptor reporter system demonstrated significant B[a]P activity relative to E2 (Clemons et al., 1998) .
B[a]P was also able to stimulate proliferation as well as alter E2 metabolism of human mammary terminal duct cell cultures (Telang et al., 1997) . In addition to the weak estrogenic activity, it has been suggested that PAHs possess antihormonal activity. This has been shown by the ability of benz[a]anthracene-3,9-diols to inhibit estrus in rats (Morreal et al., 1982) , the ability of B[a]P to decrease nuclear ER localization in breast cancer cells (Chaloupka et al., 1992) , and the inhibition of E2-induced reporter activity in a yeast-based ER transactivation system by several PAHs (Tran et al., 1996) . Furthermore, Arcaro et al., 1999 , found that B[a]P is not estrogenic in the MCF-7 focus assay. However, they observed that B[a]P could displace E2 in a whole-cell binding, but not in an in vitro competitive binding assay lacking metabolic capability, suggesting an antiestrogenic role for B[a]P metabolites in that system. The agonist activity displayed in our assay relative to the apparent antiestrogenicity in the MCF-7 focus study may be a consequence of our use of a chimeric Gal4 receptorreporter system, which lacks a functional AF-1 domain (Zacharewski et al., 1994) .
␣-NF is a well-characterized inhibitor of B[a]P metabolism in in vitro systems (Bauer et al., 1995; Crespi et al., 1985; Nesnow et al., 1982; Rämet et al., 1995) . ␣-NF has been shown to inhibit B[a]P-induced increases in intracellular Ca 2ϩ levels associated with mitogenic activity in mammary epithelial cells (Tannheimer et al., 1997) as well as the p53 expression induced by B[a]P, which correlated with DNA damage in breast adenocarcinoma cell lines (Rämet et al., 1995) .
The ability of ␣-NF, the Ah receptor antagonist (Merchant et al., 1993; Wilhelmsson et al., 1994; ) and P450 inhibitor, to significantly inhibit the response of B[a]P in our assay was the initial indicator of the possibility that B[a]P metabolites might be responsible for the observed activity. In concert with the observation that the combined activity of E2 and B[a]P could be completely inhibited by ICI but not ␣-NF demonstrated that the observed responses were mechanistically a consequence of ER-␣ activation. Together, these data indicated a potential contribution of P450 activity in the estrogenicity displayed by B[a]P, and led to the investigation as to whether the observed activity was produced by hydroxylated B[a]P metabolites.
␣-NF did not decrease the E2 response itself, with most cases showing a tendency towards increased activity. The inability of ␣-NF to significantly inhibit the combined E2 and B[a]P response was somewhat surprising and could be a consequence of interactions between the ER-and Ah receptorsignaling pathways. However, further work is required to elucidate the reasons for this observation.
The fact that ICI, but not ␣-NF, was able to block the responses of the hydroxylated B[a]P metabolites is indicative of their being the active estrogenic species in our experiments. Furthermore, the 3-OH and 9-OH metabolites of B[a]P appear to demonstrate significant displacement of E2 from the ER-␣ in in vitro binding experiments, as well as producing comparable reporter activity (Fertuck et al., manuscript in preparation) . The minimal activity produced by ␣-NF itself in the assay is in keeping with the weak binding of other flavones to the ER (Kuiper et al., 1998) .
Our present hypothesis is that the estrogenlike activity exhibited by B[a]P is predominantly produced by its hydroxylated metabolites. ␣-NF, by binding the Ah receptor, may inhibit the ability of B[a]P to induce its own metabolism, resulting in reduced activity in our assay. The ability of ␣-NF to reduce the 9-OH-B[a]P-induced luciferase activity may be a consequence of the 9-OH metabolite undergoing further metabolism to more estrogenic species or, alternatively, incurring some degree of displacement by ␣-NF from the ER.
The 7,8-OH metabolite did not demonstrate significant estrogenic activity, but had a marked effect on cell viability both by visual observation and using a ␤-galactosidase activity measure, a technique used previously in a similar system (Maness et al., 1998) . The cellular rescue effected by ␣-NF is in keeping with its ability to inhibit formation of (Ϯ)B[a] Pr7, , the ultimate B[a]P metabolite and carcinogen, via the inhibition of the monooxygenase enzyme (Vähäkangas et al., 1979) . This phenomenon has previously been observed in an engineered cell line stably expressing the P4501A1 gene (States et al., 1993) . Reduction in the sensitivity to B[a]P-mediated cytotoxicity also occurred when HepG2 cells were cultured in the presence of ␣-NF (Babich et al., 1988) .
The fact that metabolites of a ubiquitous environmental contaminant like B[a]P can potentially exhibit estrogenlike activity adds to the plethora of reported effects induced by this well-characterized DNA-reactive/genotoxic carcinogen. This calls for further analysis of the potential interactions of differing pathways, such as the role that Ah receptor activation might play in cumulative estrogen tissue responses, and its potential involvement in disease etiology.
